Gastroenterology Research of San Antonio

San Antonio, Texas 78229

4 studies enrolling now · 26 studies all time

What they study most

Colitis, Ulcerative, Colorectal Cancer, Crohn Disease, Crohn's Disease, Diabetic Gastroparesis, Eosinophilic Esophagitis, Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Obesity or Overweight, Small Bowel Crohn's Disease, Ulcerative Colitis, Ulcerative Colitis Chronic

Studies at this site

• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Recruiting now
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis — Completed
• Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D). — Stopped early
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• Endpoint Determination Study Protocol — Completed
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C" — Completed
• Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) — Completed
• Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease — Completed
• Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis — Completed
• Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients — Completed